Amplia has released its Quarterly Activities and Cash Flow Report for the quarter ended 30 June 2023.
Key highlights for the period include:
- Completion of Cohort 2 and currently dosing Cohort 3 in the Phase 1b stage of the ACCENT trial
- Reported exciting preclinical data showing AMP945 enhances the activity of an alternate treatment for pancreatic cancer called FOLFIRINOX, in a model of the disease
- Initiated a study with CSIRO to explore topical delivery of our FAK inhibitors for wound healing
- Announced the name narmafotinib for AMP945
Over the coming quarter, Amplia expects to report further progress in the ACCENT trial as we finalise dose selection for the Phase 2 portion of the trial.
Preclinical studies with AMP945 in additional indications are also underway to identify further clinical and commercial opportunities for the drug.
Read today’s ASX release.
